Adia Med Advances Towards AHCA Registration to Expand Insurance Coverage for Stem Cell Therapies
Adia Med, the medical division of Adia Nutrition (OTC Pink: ADIA), is pursuing registration with Florida's Agency for Health Care Administration (AHCA) to accept private insurance for its stem cell therapies. This initiative aims to expand access to their Autologous Hematopoietic Stem Cell Transplantation (aHSCT) and injectable stem cell treatments.
Currently operating on an out-of-pocket payment model, the company aims to reduce financial barriers through insurance coverage. The company has engaged specialized consultants for AHCA registration and financial documentation. Multiple potential clients have already received preapproval from private insurers for both HSCT and injectable stem cell therapies, indicating growing acceptance of these treatments in the insurance industry.
Adia Med, la divisione medica di Adia Nutrition (OTC Pink: ADIA), sta perseguendo la registrazione presso l'Agenzia per l'Amministrazione della Salute della Florida (AHCA) per accettare assicurazioni private per le sue terapie con cellule staminali. Questa iniziativa mira ad ampliare l'accesso ai loro Trapianti di Cellule Staminali Ematopoietiche Autologhe (aHSCT) e ai trattamenti iniettabili con cellule staminali.
Attualmente operante con un modello di pagamento diretto, l'azienda punta a ridurre le barriere finanziarie attraverso la copertura assicurativa. L'azienda ha ingaggiato consulenti specializzati per la registrazione AHCA e la documentazione finanziaria. Numerosi potenziali clienti hanno già ricevuto l'approvazione preliminare da parte di assicuratori privati per entrambe le terapie HSCT e le terapie con cellule staminali iniettabili, indicando una crescente accettazione di questi trattamenti nell'industria assicurativa.
Adia Med, la división médica de Adia Nutrition (OTC Pink: ADIA), está buscando la inscripción en la Agencia de Administración de Atención Médica de Florida (AHCA) para aceptar seguros privados para sus terapias con células madre. Esta iniciativa tiene como objetivo ampliar el acceso a sus Trasplantes de Células Madre Hematopoyéticas Autólogas (aHSCT) y tratamientos inyectables de células madre.
Actualmente opera bajo un modelo de pago directo, la empresa busca reducir las barreras financieras a través de la cobertura del seguro. La empresa ha contratado consultores especializados para la inscripción en la AHCA y la documentación financiera. Varios clientes potenciales ya han recibido la aprobación previa de aseguradoras privadas para tanto HSCT como terapias inyectables de células madre, lo que indica una creciente aceptación de estos tratamientos en la industria del seguro.
Adia Med, Adia Nutrition(OTC Pink: ADIA)의 의료 부문, 플로리다 건강 관리 관리국(AHCA)에 등록하여 자사 줄기세포 치료에 대한 민간 보험을 수용하려고 합니다. 이 이니셔티브는 그들의 자체 조혈 줄기세포 이식(aHSCT) 및 주사 가능한 줄기세포 치료에 대한 접근을 확대하는 것을 목표로 합니다.
현재 자비 지불 모델로 운영되고 있는 이 회사는 보험 적용을 통해 재정적 장벽을 줄이는 것을 목표로 하고 있습니다. 회사는 AHCA 등록 및 재무 문서를 위해 전문 컨설턴트를 고용했습니다. 여러 잠재 고객이 HSCT 및 주사 가능한 줄기세포 치료에 대해 민간 보험사로부터 사전 승인을 이미 받았으며, 이는 보험 산업 내에서 이러한 치료법에 대한 수용이 증가하고 있음을 나타냅니다.
Adia Med, la division médicale d'Adia Nutrition (OTC Pink: ADIA), cherche à s'enregistrer auprès de l'Agence de l'Administration des Soins de Santé de Floride (AHCA) afin d'accepter les assurances privées pour ses thérapies par cellules souches. Cette initiative vise à élargir l'accès à leurs Transplantations Autologues de Cellules Souches Hématopoïétiques (aHSCT) et traitements injectables de cellules souches.
Actuellement opérant sur un modèle de paiement direct, l'entreprise vise à réduire les barrières financières grâce à la couverture d'assurance. L'entreprise a engagé des consultants spécialisés pour l'enregistrement auprès de l'AHCA et la documentation financière. Plusieurs clients potentiels ont déjà obtenu une pré-approbation de la part d'assureurs privés pour les thérapies HSCT et les thérapies par cellules souches injectables, indiquant une acceptation croissante de ces traitements dans l'industrie de l'assurance.
Adia Med, die medizinische Abteilung von Adia Nutrition (OTC Pink: ADIA), strebt die Registrierung bei der Gesundheitsbehörde von Florida (AHCA) an, um private Versicherungen für ihre Stammzelltherapien zu akzeptieren. Dieses Vorhaben zielt darauf ab, den Zugang zu ihren autologen hämatopoetischen Stammzelltransplantationen (aHSCT) und injizierbaren Stammzellbehandlungen zu erweitern.
Derzeit arbeitet das Unternehmen nach einem Selbstzahler-Modell und möchte finanzielle Barrieren durch eine Versicherungsschutz verringern. Das Unternehmen hat spezialisierte Berater für die AHCA-Registrierung und die Finanzdokumentation engagiert. Mehrere potenzielle Kunden haben bereits eine Vorabgenehmigung von privaten Versicherern für sowohl HSCT als auch injizierbare Stammzelltherapien erhalten, was auf eine wachsende Akzeptanz dieser Behandlungen in der Versicherungsbranche hinweist.
- Multiple potential clients have received preapproval from private insurers
- Expansion into insurance coverage could significantly increase patient access and revenue potential
- Growing acceptance of stem cell treatments by insurance providers indicates market validation
- Currently to out-of-pocket payments, restricting market reach
- AHCA approval still pending with no guaranteed timeline
- Regulatory compliance costs and consulting expenses may impact short-term financials
Winter Park, Florida--(Newsfile Corp. - February 13, 2025) - Adia Med, the medical division of Adia Nutrition Inc. (OTC Pink: ADIA), proudly announces its ongoing registration with the State of Florida's Agency for Health Care Administration (AHCA). This crucial initiative is designed to secure approval for accepting private insurance for Adia Med's pioneering stem cell therapies including Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatment and injectable stem cells, thereby increasing accessibility to this life-altering therapy across the United States.
Adia Med Advances Towards AHCA Registration to Expand Insurance Coverage for Stem Cell Therapies
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/240465_img_5217.jpg
"Registering with the AHCA is a monumental step in our mission to provide open access to our groundbreaking therapies for a maximal number of people," stated Larry Powalisz, CEO of Adia Nutrition. "Upon approval, we'll collaborate with private insurers to lift the financial barriers that currently restrict patient access, broadening our nationwide community impact."
Until now, Adia Med's operations have depended solely on out-of-pocket payments from patients. However, the shift to accepting private insurance promises to transform patient care by:
Increasing Affordability: By lowering the cost barrier, AHSCT and injectable stem cell treatments will be within reach for a broader demographic, significantly reducing the financial strain on individuals seeking these advanced medical solutions.
Enhancing Accessibility: More patients will have the opportunity to benefit from these therapies without the immediate financial burden, fostering health equity.
Strengthening Partnerships: Developing robust relationships with insurance providers to integrate Adia Med's treatments into various health coverage plans.
The AHCA approval process demands rigorous adherence to Florida's healthcare standards, ensuring facilities maintain excellence in care, safety, and operational protocols. Adia Med's pursuit of this approval highlights its dedication to both quality service and patient welfare.
"To facilitate this transition, we've engaged a specialized consultant to meticulously handle the AHCA registration paperwork, alongside a financial expert to review and submit our financial data," noted Dr. Kalpesh Barot, lead physician of AHSCT at Adia Med. "We are fully committed to surpassing the AHCA's stringent criteria."
On the significance of AHCA approval, Larry Powalisz added, "The AHCA plays a pivotal role in healthcare regulation in Florida, ensuring that facilities like ours adhere to the highest standards of medical practice. This approval will affirm our status as a trusted provider, significantly boosting investor confidence and attracting more partnerships."
Dr. Barot further emphasized, "The AHCA's involvement is crucial as it validates our treatment protocols and operational integrity, which in turn, opens doors to insurance coverage, thus making our treatments more accessible to those in need."
Moreover, Adia Med has been contacted by multiple potential clients who have already been preapproved by select private insurers for either HSCT therapy or injectable stem cell therapy. This development represents a seismic shift within the medical industry, where insurers seem to be broadening their scope of coverage to include non-traditional treatments. This trend signifies a growing acceptance and recognition of innovative treatments like those offered by Adia Med.
As Adia Med waits for AHCA's nod, the organization is preparing for this new operational phase, confident in its compliance and the potential to revolutionize patient care through broader insurance coverage. Adia Med's strategic move towards AHCA approval is part of a larger vision to integrate into the mainstream healthcare ecosystem, offering hope and advanced medical solutions to an ever-widening audience.
For media inquiries or further information, please contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adia-med.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/240465
FAQ
What is the significance of AHCA registration for ADIA's stem cell therapy business?
How does ADIA currently handle payment for stem cell treatments?
What types of stem cell treatments does ADIA offer?
Have any insurance companies pre-approved ADIA's stem cell treatments?
What steps is ADIA taking to secure AHCA approval?
